A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Saved in:
Bibliographic Details
Published in:Hematological oncology Vol. 39; no. S2
Main Authors: Torka, P., Groman, A., Wong, J., Baysal, B., Nichols, J., Kader, A., Mavis, C., Jani Sait, S., Block, A., Przespolewski, E., Mohr, A., Lund, I., McWhite, K., Kostrewa, J., DeMarco, J., Johnson, M., Darrall, A., Thomas, R.‐N., Sundaram, S., Ghione, P., Hutson, A., Hernandez‐Ilizaliturri, F.
Format: Journal Article
Language:English
Published: Chichester Wiley Subscription Services, Inc 01-06-2021
Subjects:
B-cell lymphoma
Carboplatin
Etoposide
Ifosfamide
Immunotherapy
Lymphoma
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.83_2881